The DOI matches its Crossref record; 75 of the 76 references it cites were found in a registry or an index.
Analgesic Effects of Fatty Acid Amide Hydrolase Inhibition in a Rat Model of Neuropathic Pain
Open accessAbstract
Cannabinoid-based medicines have therapeutic potential for the treatment of pain. Augmentation of levels of endocannabinoids with inhibitors of fatty acid amide hydrolase (FAAH) is analgesic in models of acute and inflammatory pain states. The aim of this study was to determine whether local inhibition of FAAH alters nociceptive responses of spinal neurons in the spinal nerve ligation model of neuropathic pain. Electrophysiological studies were performed 14-18 d after spinal nerve ligation or sham surgery, and the effects of the FAAH inhibitor cyclohexylcarbamic acid 3-carbamoyl biphenyl-3-yl ester (URB597) on mechanically evoked responses of spinal neurons and levels of endocannabinoids were determined. Intraplantar URB597 (25 microg in 50 microl) significantly (p < 0.01) attenuated mechanically evoked responses of spinal neurons in sham-operated rats. Effects of URB597 were blocked by the cannabinoid 1 receptor (CB1) antagonist AM251 [N-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide] (30 microg in 50 microl) and the opioid receptor antagonist naloxone. URB597 treatment increased levels of anandamide, 2-arachidonyl glycerol, and oleoyl ethanolamide in the ipsilateral hindpaw of sham-operated rats. Intraplantar URB597 (25 microg in 50 microl) did not, however, alter mechanically evoked responses of spinal neurons in spinal nerve ligated (SNL) rats or hindpaw levels of endocannabinoids. Intraplantar injection of a higher dose of URB597 (100 microg in 50 microl) significantly (p < 0.05) attenuated evoked responses of spinal neurons in SNL rats but did not alter hindpaw levels of endocannabinoids. Spinal administration of URB597 attenuated evoked responses of spinal neurons and elevated levels of endocannabinoids in sham-operated and SNL rats. These data suggest that peripheral FAAH activity may be altered or that alternative pathways of metabolism have greater importance in SNL rats.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the same study, spinal administration of URB597 was equally efficacious at attenuating mechanically-evoked responses and increasing levels of endogenous cannabinoids in SNL and sham rats and these effects were CB1-mediated.92”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [92]
In the citing paper
“The antinociceptive effects of URB597 were blocked by a CB1-specific antagonist in both sham and SNL rats.92”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [92]
In the citing paper
“Low doses of locally injected URB597 (i.pl.) reduced mechanically-evoked responses of WDR neurons and increased endocannabinoid levels in ipsilateral paw tissue of sham operated rats.92”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [92]
In the citing paper
“A four-fold higher dose was required for reduction of mechanically-evoked WDR neuronal responses in SNL rats; these rats showed no corresponding increase in endocannabinoid levels, suggesting that contributions of FAAH to endocannabinoid metabolism may be modified under conditions of neuropathic nociception.92”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [92]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantitative assessment of tactile allodynia in the rat paw
Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M., & Yaksh, T. L. (1994) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(94)90144-9 · Cited by 7,740
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Ho Kim, S., & Mo Chung, J. (1992) · Pain · doi:10.1016/0304-3959(92)90041-9 · Cited by 3,069
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H.-H., Sørgård, M., Di Marzo, V., Julius, D., & Högestätt, E. D. (1999) · Nature · doi:10.1038/22761 · Cited by 2,142
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
Brain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373
Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
Control of pain initiation by endogenous cannabinoids
Calignano, A., Rana, G. L., Giuffrida, A., & Piomelli, D. (1998) · Nature · doi:10.1038/28393 · Cited by 1,069
An endocannabinoid mechanism for stress-induced analgesia
Hohmann, A. G., Suplita, R. L., Bolton, N. M., Neely, M. H., Fegley, D., Mangieri, R., Krey, J. F., Michael Walker, J., Holmes, P. V., Crystal, J. D., et al. (2005) · Nature · doi:10.1038/nature03658 · Cited by 778
The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)
Smart, D., Gunthorpe, M. J., Jerman, J. C., Nasir, S., Gray, J., Muir, A. I., Chambers, J. K., Randall, A. D., & Davis, J. B. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703050 · Cited by 775
Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist
Deutsch, D. G., & Chin, S. A. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90486-g · Cited by 706
Ibrahim, M. M., Porreca, F., Lai, J., Albrecht, P. J., Rice, F. L., Khodorova, A., Davar, G., Makriyannis, A., Vanderah, T. W., Mata, H. P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409888102 · Cited by 521
Fegley, D., Gaetani, S., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078980 · Cited by 427
Fox, A., Kesingland, A., Gentry, C., McNair, K., Patel, S., Urban, L., & James, I. (2001) · Pain · doi:10.1016/s0304-3959(00)00474-7 · Cited by 379
Anandamide Amidohydrolase Activity in Rat Brain Microsomes
Desarnaud, F., Cadas, H., & Piomelli, D. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.11.6030 · Cited by 336
Lichtman, A. H., Leung, D., Shelton, C. C., Saghatelian, A., Hardouin, C., Boger, D. L., & Cravatt, B. F. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.069401 · Cited by 332
Anandamide amidohydrolase reacting with 2‐arachidonoylglycerol, another cannabinoid receptor ligand
Goparaju, S. K., Ueda, N., Yamaguchi, H., & Yamamoto, S. (1998) · FEBS Letters · doi:10.1016/s0014-5793(97)01603-7 · Cited by 328
Herzberg, U., Eliav, E., Bennett, G. J., & Kopin, I. J. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(96)13308-5 · Cited by 307
Ueda, N., Kurahashi, Y., Yamamoto, S., & Tokunaga, T. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.40.23823 · Cited by 303
Lichtman, A. H., Shelton, C. C., Advani, T., & Cravatt, B. F. (2004) · Pain · doi:10.1016/j.pain.2004.01.022 · Cited by 301
Maione, S., Bisogno, T., de Novellis, V., Palazzo, E., Cristino, L., Valenti, M., Petrosino, S., Guglielmotti, V., Rossi, F., & Marzo, V. D. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.093286 · Cited by 299
Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models
Jayamanne, A., Greenwood, R., Mitchell, V. A., Aslan, S., Piomelli, D., & Vaughan, C. W. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706510 · Cited by 287
Bisogno, T., Sepe, N., Melck, D. J., Maurelli, S., PETROCELLIS, L. D., & Marzo, V. D. (1997) · Biochemical Journal · doi:10.1042/bj3220671 · Cited by 277
Dickenson, A. H., & Sullivan, A. F. (1986) · Pain · doi:10.1016/0304-3959(86)90044-8 · Cited by 270
Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels
van der Stelt, M., Trevisani, M., Vellani, V., PETROCELLIS, L. D., Moriello, A. S., Campi, B., McNaughton, P. A., Geppetti, P., & Marzo, V. D. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600784 · Cited by 243
Ueda, N., Yamanaka, K., & Yamamoto, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106261200 · Cited by 242
Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus
Makara, J. K., Mor, M., Fegley, D., Szabó, S. I., Kathuria, S., Astarita, G., Duranti, A., Tontini, A., Tarzia, G., Rivara, S., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1521 · Cited by 235
Bridges, D., Ahmad, K., & Rice, A. S. C. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704110 · Cited by 222
Goparaju, S. K., Ueda, N., Taniguchi, K., & Yamamoto, S. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00314-1 · Cited by 212
Maurelli, S., Bisogno, T., PETROCELLIS, L. D., Luccia, A. D., Marino, G., & Marzo, V. D. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)01311-3 · Cited by 200
Lim, G., Sung, B., Ji, R.-R., & Mao, J. (2003) · Pain · doi:10.1016/s0304-3959(03)00242-2 · Cited by 195
VR1, but not P2X3, increases in the spared L4 DRG in rats with L5 spinal nerve ligation
Fukuoka, T., Tokunaga, A., Tachibana, T., Dai, Y., Yamanaka, H., & Noguchi, K. (2002) · Pain · doi:10.1016/s0304-3959(02)00067-2 · Cited by 190
Clement, A. B., Hawkins, E. G., Lichtman, A. H., & Cravatt, B. F. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-09-03916.2003 · Cited by 187
Hypoactivity of the Spinal Cannabinoid System Results in NMDA-Dependent Hyperalgesia
Richardson, J. D., Aanonsen, L., & Hargreaves, K. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-01-00451.1998 · Cited by 182
Chapman, V., Suzuki, R., & Dickenson, A. H. (1998) · The Journal of Physiology · doi:10.1111/j.1469-7793.1998.881bs.x · Cited by 173
Holt, S., Comelli, F., Costa, B., & Fowler, C. J. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706348 · Cited by 168
Richardson, D. S., Ortori, C. A., Chapman, V., Kendall, D. A., & Barrett, D. A. (2006) · Analytical Biochemistry · doi:10.1016/j.ab.2006.10.039 · Cited by 168
Saario, S. M., Savinainen, J. R., Laitinen, J. T., Järvinen, T., & Niemi, R. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.12.003 · Cited by 167
Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms
Chang, L., Luo, L., Palmer, J. A., Sutton, S. W., Wilson, S. J., Barbier, A., Breitenbucher, J. G., Chaplan, S. R., & Webb, M. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706773 · Cited by 166
Hohmann, A. G. (2002) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(02)00154-8 · Cited by 161
Elmes, S. J. R., Jhaveri, M. D., Smart, D., Kendall, D. A., & Chapman, V. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03690.x · Cited by 160
Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms
Chang, L., Luo, L., Palmer, J. A., Sutton, S., Wilson, S. J., Barbier, A. J., Breitenbucher, J. G., Chaplan, S. R., & Webb, M. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706699 · Cited by 155 · cited 2×
“Previously, it has been shown that a single dose of systemic URB597 does not alter neuropathic pain behavior (Jayamanne et al., 2006), whereas the FAAH inhibitor OL135 attenuated allodynia in neuropathic rats (Chang et al., 2006).”
BackgroundSagar, D. R., Kelly, S., Millns, P. J., O'Shaughnessey, C. T., Kendall, D. A., & Chapman, V. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04206.x · Cited by 154
SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice
Richardson, J. D., Aanonsen, L., & Hargreaves, K. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00952-1 · Cited by 149
Rashid, H., Inoue, M., Kondo, S., Kawashima, T., Bakoshi, S., & Ueda, H. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046250 · Cited by 139
Oxidative Metabolism of Endocannabinoids by COX-2
Kozak, K. R., Prusakiewicz, J. J., & Marnett, L. J. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043453081 · Cited by 136
Weber, A., Ni, J., Ling, K.-H. J., Acheampong, A., Tang‐Liu, D. D., Burk, R. M., Cravatt, B. F., & Woodward, D. F. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m300475-jlr200 · Cited by 129
Fowler, C. J., Jonsson, K., & Tiger, G. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00712-2 · Cited by 129
Scott, D. A., Wright, C. E., & Angus, J. A. (2004) · Pain · doi:10.1016/j.pain.2004.01.020 · Cited by 129
Rashid, M. H., Inoue, M., Bakoshi, S., & Ueda, H. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.050948 · Cited by 123
A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats
Pascual, D., Goicoechea, C., Suardíaz, M., & Martín, M. I. (2005) · Pain · doi:10.1016/j.pain.2005.07.008 · Cited by 117
Substrate Specificity and Stereoselectivity of Rat Brain Microsomal Anandamide Amidohydrolase
Lang, W., Qin, C., Lin, S., Khanolkar, A. D., Goutopoulos, A., Fan, P., Abouzid, K. A. M., Meng, Z., Biegel, D., & Makriyannis, A. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980461j · Cited by 115
Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity
Strangman, N. M., Patrick, S. L., Hohmann, A. G., Tsou, K., & Walker, J. M. (1998) · Brain Research · doi:10.1016/s0006-8993(98)01031-2 · Cited by 109
Anandamide: an endogenous activator of the vanilloid receptor
Smart, D., & Jerman, J. C. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01459-0 · Cited by 107
Two distinctive antinociceptive systems in rats with pathological pain
Mao, J., Price, D. D., Lü, J., Keniston, L., & Mayer, D. J. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00998-2 · Cited by 104
Sun, Y., Tsuboi, K., Zhao, L., Okamoto, Y., Lambert, D. M., & Ueda, N. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2005.08.010 · Cited by 103
An acid amidase hydrolyzing anandamide as an endogenous ligand forcannabinoid receptors
Ueda, N., Yamanaka, K., Terasawa, Y., & Yamamoto, S. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00820-0 · Cited by 100
de Lago, E., Petrosino, S., Valenti, M., Morera, E., Ortega‐Gutiérrez, S., Fernández‐Ruíz, J., & Marzo, V. D. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.05.011 · Cited by 86
Helyes, Z., Németh, J., Thán, M., Bölcskei, K., Pintér, E., & Szolcsányi, J. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00651-9 · Cited by 85
Identification and Partial Characterization
Wintroub, B. U., Kaempfer, C. E., Schechter, N. M., & Proud, D. (1986) · Cited by 85
Ueda, N. (2002) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(02)00053-9 · Cited by 82
Johanek, L. M., & Simone, D. A. (2004) · Pain · doi:10.1016/j.pain.2004.02.020 · Cited by 78
Chapman, V. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702758 · Cited by 72
Tsuboi, K., HILLIGSMANN, C., Vandevoorde, S., Lambert, D. M., & Ueda, N. (2004) · Biochemical Journal · doi:10.1042/bj20031695 · Cited by 70
Monhemius, R., Azami, J., Green, D. L., & Roberts, M. H. T. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02605-1 · Cited by 64
Jhaveri, M. D., Elmes, S. J. R., Kendall, D. A., & Chapman, V. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04227.x · Cited by 63
Maldonado, R. J., & Valverde, O. (2003) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2003.08.001 · Cited by 62
MacDonald, R. E., Bingham, S., Bond, B. C., Parsons, A. A., & Philpott, K. L. (2001) · Molecular Brain Research · doi:10.1016/s0169-328x(01)00086-9 · Cited by 47
Mulder, A. M., & Cravatt, B. F. (2006) · Biochemistry · doi:10.1021/bi061122s · Cited by 44
Dogrul, A. B., Gardell, L. R., Ma, S.-W., Ossipov, M. H., Porreca, F., & Lai, J. Y. (2002) · Pain · doi:10.1016/s0304-3959(02)00302-0 · Cited by 34
The potency of the fatty acid amide hydrolase inhibitor URB597 is dependent upon the assay pH
Paylor, B., Holt, S., & Fowler, C. J. (2006) · Pharmacological Research · doi:10.1016/j.phrs.2006.07.006 · Cited by 33
A hydrolase enzyme inactivating endogenous ligands for cannabinoid receptors.
Ueda, N., Goparaju, S. K., Katayama, K., Kurahashi, Y., Suzuki, H., & Yamamoto, S. (1998) · PubMed · Cited by 23
Spinal GABAB-receptor antagonism increases nociceptive transmission in vivo
Sokal, D. M., & Chapman, V. (2001) · Neuroreport · doi:10.1097/00001756-200110290-00021 · Cited by 15
Research works printed but not linked: 1
- Wilson AW Clayton NM Medhurst SJ Bountra C Chessel IP (2004) The FAAH inhibitor URB597 reverses inflammatory pain through a CB1 receptor mediated mechanism. Proceedings of the British Pharmacological Society, Retrieved November 21, 2006 from http://www.pA2online.org/Vol2Issue4abst049P.html .
Cited by
Sorted by citations
Targeting the endocannabinoid system: to enhance or reduce?
Marzo, V. D. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 822
Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system
Schlosburg, J. E., Blankman, J. L., Long, J. Z., Nomura, D. K., Pan, B., Kinsey, S. G., Nguyen, P. T., Ramesh, D., Booker, L., Burston, J. J., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2616 · Cited by 641
Enzymatic pathways that regulate endocannabinoid signaling in the nervous system
Ahn, K., McKinney, M. K., & Cravatt, B. F. (2008) · Chemical Reviews · doi:10.1021/cr0782067 · Cited by 529
The Endocannabinoid System and Pain
Guindon, J., & Hohmann, A. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824660 · Cited by 476
Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside
Rahn, E. J., & Hohmann, A. G. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.08.002 · Cited by 305
Metadata
- Authors
- Jhaveri, M. D., Richardson, D., Kendall, D. A., Barrett, D. A., & Chapman, V.
- Affiliations
- University of Nottingham (GB)
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2006-12-20
- Volume
- 26
- Issue
- 51
- Pages
- 13318-13327
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6674985
- OpenAlex
- W2037393750
- Cited by
- 159
- References
- 76
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 5 · 2019: 3 · 2018: 5 · 2017: 7 · 2016: 7 · 2015: 5 · 2014: 11 · 2013: 9 · 2012: 14
- FWCI
- 12.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Nottingham ePrints (University of Nottingham) (submittedVersion, cc-by)
- Repository@Nottingham (University of Nottingham) (submittedVersion, other-oa)
- Funders
- Wellcome Trust
- Directorate for Biological Sciences
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
- Keywords
- fatty acid amide hydrolase inhibition, neuropathic pain, spinal nerve ligation, URB597, endocannabinoids, anandamide, 2-arachidonoylglycerol, oleoylethanolamide, cannabinoid 1 receptor, AM251, naloxone, mechanical nociception, spinal cord neurons, analgesia
- MeSH terms
- Fatty Acid Amide Hydrolases, Amidohydrolases, Analgesics, Animals, Benzamides, Carbamates, Disease Models, Animal, Enzyme Inhibitors, Injections, Spinal, Male, Pain, Pain Measurement, Rats, Sprague-Dawley, Receptor, Cannabinoid, CB1, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
